Cancer Immunotherapy Out of the Gate : The 22 nd Annual Cancer Research Institute International Immunotherapy
نویسندگان
چکیده
The 22nd annual Cancer Research Institute (CRI) International Immunotherapy Symposiumwasheld fromOctober 5–8, 2014, in New York City. Titled "Cancer Immunotherapy: Out of the Gate," the symposiumbeganwith a Cancer Immunotherapy Consortium satellite meeting focused on issues in immunotherapy drug development, followed by five speaker sessions and a poster session devoted to basic and clinical cancer immunology research. The second annual William B. Coley lecture was delivered by Lieping Chen, one of the four recipients of the 2014 William B.ColeyAward forDistinguishedResearch inTumor Immunology; the other three recipients were Gordon Freeman, Tasuku Honjo, and Arlene Sharpe. Prominent themes of the conference were the use of genomic technologies to identify neoantigens and the emergence of new immune modulatory molecules, beyond CTLA-4 and PD-1/PD-L1, as new therapeutic targets for immunotherapy. Cancer Immunol Res; 3(5); 444–8. 2015 AACR.
منابع مشابه
اثر ایمونوتراپی سرطان پروستات بر بیان ژنesp انتروکوکوس فکالیس
Background: Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer deaths among men in the world. Immunotherapy is a new, non-invasive and effective method for the treatment of cancer, but its side effects on the normal flora of bacteria and opportunistic infections not known yet. The aim of this study was to evaluate the effects of immunotherapy on Ent...
متن کاملImmunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملFuture of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...
متن کاملIn vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies
Objective(s): Lung cancer is the main leading cause of cancer death worldwide. Angiogenesis is the main step in proliferation and spreading of tumor cells. Targeting vascular endothelial growth factor (VEGF) is an effective approach for inhibition of cancer angiogenesis. Nanobodies (NBs) are a novel class of antibodies derived from the camel. Unique characteristics of Nbs like their small size ...
متن کاملایمونوتراپی تومور، تاریخچه و دست آورد ها
Cancer treatment is one of the main fields in basic and clinical research. Immunotherapy or using immune response is considered as one of the most important and effective complementary approaches in cancer therapy after surgery, chemotherapy and radiotherapy. In recent years many clinical trials have investigated this approach. The complications involved in immune response against a tumor calls...
متن کامل